Therefore, the expression of MYC and RUNX2 functions to confer survival and proliferative effects on leukemic precursors such as MDPs that initiated BPDCN in vivo, but also impedes terminal differentiation into pDCs to promote the development of BPDCN. Here, MYC is linked to CD4+/CD56+ hematodermic neoplasm.